Notre Dame researchers report progress on compound to treat neurological diseases

Results of a study by a group of University of Notre Dame, USA, researchers represent a promising step on the road to developing new drugs for a variety of neurological diseases. The group from the University's Departments of Chemistry and Biochemistry and Biological Sciences and the Friemann Life Sciences Center focused on the design, synthesis and evaluation of water-soluble "gelatinase inhibitor" compounds.

Gelatinases, a class of enzymes, have been implicated in a host of human diseases from cancer to cardiovascular conditions and in particular neurological conditions such as stroke, aneurysm and traumatic brain injury. Researchers have increasingly focused on developing potent gelatinase inhibitor drugs to treat acute gelatinase-dependent diseases.

Variants of SB-3CT